40 Million Doses of Serum Institute’s COVID-19 Vaccine Under ‘At-Risk’ Manufacturing, Stockpiling License
The Serum Institute of India (SII) has manufactured 40 million doses of the vaccine against coronavirus, which is currently on the Phase 3 of clinical trials, to avoid a shortage after it gets approval from the government of India. However, the Covishield vaccine, jointly developed by AstraZeneca and Oxford University, is currently under the ‘at-risk’ manufacturing and stockpiling license from the Central Drugs Standard Control Organisation (CDSCO).
The plan of the Serum Institute is to stockpile 200 to 300 million doses by January in 2021 joo, with the half of the total vaccine doses expected to be available for the Indians.
According to the Serum Institute and the Indian Council of Medical Research (ICMR), as many as 1,600 people have enrolled for participation in the Phase 3 human trials of the vaccine. With the help of the ICMR, the Serum Institute will aim to make the vaccine available for the Indians on priority basis.
“The promising results of the trials so far give confidence that Covishield could be a realistic solution to the deadly pandemic. Covishield is by far the most advanced vaccine in human testing in India,” the Serum Institute stated.
By 2021, the Serum Institute is expected to supply 200 million doses to Gavi, Bill and Melinda Gates Foundation and the Vaccine Alliance at a maximum price of $3 per dose. The vaccine will be first available for the low and medium income countries. The vaccine is being developed in the UK and the Phase 3 clinical trials are underway in countries like the UK, South Africa, Brazil and the USA.
Subscribe for newsletter
* You will receive the latest news and updates